Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives

Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavalle, Carlo, Trivigno, Sara, Vetta, Giampaolo, Magnocavallo, Michele, Mariani, Marco Valerio, Santini, Luca, Forleo, Giovanni Battista, Grimaldi, Massimo, Badagliacca, Roberto, Lanata, Luigi, Ricci, Renato Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397118/
https://www.ncbi.nlm.nih.gov/pubmed/34441994
http://dx.doi.org/10.3390/jcm10163696
Descripción
Sumario:Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.

Ejemplares similares